Applied DNA Sciences Holds Special Meeting of Stockholders

On January 23, 2025, Applied DNA Sciences, Inc. (NASDAQ:APDN) conducted a special meeting of stockholders, where shareholders voted on critical matters affecting the company. At the convening, a total of 14,062,557 shares of the company’s common stock were represented either in person or by proxy and had voting rights. However, this fell short of constituting a quorum according to the company’s By-Laws, which mandates one-third of the total outstanding common stock to be present. Consequently, no decisions were made regarding the proposal initially brought forth, prompting the adjournment of the Special Meeting until February 14, 2025, at 11:00 a.m. This delay was intended to enable further outreach to shareholders and afford them more time to vote on the sole proposal put forth during the Special Meeting.

As per the details outlined in the Form 8-K submission dated October 31, 2024, Applied DNA Sciences successfully concluded a registered direct public offering simultaneously with a private placement, collectively referred to as the Offering. This financial event involved the issue of common stock, series C and D common stock purchase warrants termed as Series Warrants, and placement agent warrants identified as Placement Agent Warrants, which along with the Series Warrants are termed as the Private Placement Warrants. The exercisability of the Private Placement Warrants is subject to the Warrant Stockholder Approval as prescribed by the regulations of the Nasdaq Capital Market. Notably, in the absence of securing the Warrant Stockholder Approval during the Special Meeting, Applied DNA Sciences is obligated to summon a subsequent stockholder meeting to elicit the necessary consent.

The Company’s leadership, as reflected in the filing, remains committed to fulfilling all regulatory requirements and upholding transparent communication with its shareholders. James A. Hayward, the Chief Executive Officer of Applied DNA Sciences, has duly signed the report on behalf of the Company in compliance with the provisions of the Securities Exchange Act of 1934. The company’s diligence and adherence to regulatory norms underscore its dedication to maintaining sound corporate governance practices.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Applied DNA Sciences’s 8K filing here.

About Applied DNA Sciences

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.